Feb 19 (Reuters) - German biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNEXSPIKE infringes a patent related to BioNTech and Pfizer's competing shot Comirnaty.

Moderna (MRNA) faces a lawsuit in the U.S. for allegedly infringing patent rights related to the COVID-19 shot developed by Pfizer (PFE) and BioNTech (BNTX), marking the latest such case among COVID-19 vaccine makers.

In 2025, Moderna spent $3.1 billion on R&D, a 31% decrease from the $4.5 billion budget (PDF) in 2024 and a further drop from the $4.8 billion spent in 2023.

CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults aged 50 years and older. The Company has filed for ...

Moderna Inc. said its vaccine to prevent cytomegalovirus, a common cause of birth defects, failed to meet its goal in a late-stage trial, a setback for the company still struggling to move past the pandemic. The study didn’t meet its primary endpoint of ...

Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.